SICA-HF is a prospective, multicentre, multinational, longitudinal, pathophysiological evaluation study, which is being conducted in 11 centres across six countries. SICA-HF receives funding from the European commission's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 241558 (SICA-HF) and from the Russian Ministry of Science and Education within the file transfer protocol "R\&D in priority fields of the S\&T complex of Russia 2007-2012" under state contract number 02.527.11.0007. The aim of SICA-HF is to provide detailed characteristics of co-morbidities of heart failure at baseline and over time, particularly with regards to obesity, cachexia, and type 2 diabetes.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
* Clinical diagnosis of heart failure;
* Objective evidence of cardiac dysfunctions as evidenced by at least ONE of the following:
* left ventricular ejection fraction ≤ 40%;
* left atrial dimension \>4.0 cm (or \>2.5 cm/m in height)
* NT-proBNP \>400 pg/ml \[\>47.3 pmol/l\] (or BNP \>150 pg/ml)
* Current treatment with loop diuretics;
* Age \>18 years;
* Willingness to provide informed consent
Exclusion criteria:
* Congenital heart disease;
* Any life-threatening disease other than heart failure;
* Active malignancy of any type, or history of a malignancy within previous 5 years;
* Previous heart transplantation;
* Intra-venous therapy for heart failure given within the previous 72 hours;
* Severe neuro-muscular disease;
* History of unstable angina, myocardial infarction or stroke within 3 months prior to the study;
* Pregnancy;
* Treatment with immunosuppressive therapy, e.g. steroids for rheumatoid arthritis or obstructive lung disease;
* Significant renal dysfunction, defined as serum creatinine \>250 μmol/L \[\>2.8 mg/dL\];
* Severe liver disease, defined as any liver function tests \>3 times the upper limit of normal;
* Unable to understand and comply with protocol or to give informed consent.
What they're measuring
1
Prevalence, incidence, persistence and phenotype of obesity, cachexia and type 2 diabetes in patients with chronic heart failure.